1. I-MM, i-Jemal A, iLortet-Tieulent J, iWard E, u-Ferlay J, uBrawley O, uBray F:
Ukwahlukana ngamazwe ngamazwe kwimeko yomhlaza wesibeletho kunye nokufa kwabantu.
I-Eur Urol 2012, 61:1079�1092.
2. EMasko EM, Allott EH, Freedland SJ: Ubudlelwane phakathi kokutya kunye
Umhlaza wesibeleko: ngaba usoloko ungcono? I-Eur Urol 2013, 63:810�820.
3. UMavropoulos JC, u-Isaacs WB, i-Pizzo SV, i-Freedland SJ: Ngaba kukho inxaxheba
ukutya kwe-carbohydrate ketogenic ekulawuleni umhlaza wesibeletho?
Urology 2006, 68:15�18.
4. Freedland SJ, Mavropoulos J, Wang A, uDarshan M, uDeark-Wahnefried W,
Aronson WJ, Cohen P, Hwang D, uPetererson B, ii-Fields T, i-Pizzo SV, u-Isaacs WB:
Umngcipheko we-carbohydrate, ukwanda komdlavuza weprotate, kunye ne-insulin
ukukhula kwe-axis. Prostate 2008, 68:11�19.
5. I-Mavropoulos JC: I-Buschemeyer WC 3rd, uTewari AK, uRokhfeld D, uPollak M,
Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W,
I-Westman EC, uPetererson BL, uPizzo SV, i-Freedland SJ: Imiphumo yokuhluka
I-carbohydrate yokutya kunye nomxholo wamanqatha kwi-LNCaP yomlambo
umhlaza wesifo seprotate xenograft model. I-Cancer Prev Res (Phila Pa) 2009,
2: 557-565.
6. EMasko EM, Thomas JA 2nd, uAntonelli JA, uLloyd JC, Phillips TE, Poulton SH,
Dewhirst MW, Pizzo SV, Freedland SJ: Izidlo eziphantsi kwe-carbohydrates kunye
Umhlaza wedlala lobudoda: uphantsi kangakanani �uphantsi ngokwaneleyo�? Cancer Prev Res (Phila) 2010,
3: 1124-1131.
7. UDrake I, Sonestedt E, Gullberg B, Ahlgren G, Bjartell A, Wallstrom P, Wirf�lt E:
Ukutya okunomdla wee-carbohydrates ngokumalunga nomngcipheko womhlaza wesifo somhlaza: a
oza kufundelwa kwi-Malmo Diet kunye neqela leCarcer. Am J Clin Nutrition
2012, 96:1409�1418.
8. Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B: Metformin
inqanda ukuguquka kwe-epithelial-mesenchymal kumaseli omhlaza wesibeletho:
Ukubandakanywa kwe-tumor suppressor miR30a kunye negalelo layo le-SOX4.
I-Biochem Biophys Res Commun 2014, 452:746�752.
9. U-Lee SY, Ingoma CH, Xie YB, Jung C, Choi HS, Lee K
i-metformin inqanda umsebenzi we-androgen receptor kwisifo somhlaza wesibeletho
iiseli. Umhlaza Lett 2014, 354:390�397.
10. Demir U, Koehler A, Schneider R, Schweiger S, Klocker H: I-Metformin antitumor
isiphumo ngokuphazamiseka komlawuli we-MID1 we-translation complex
kunye nokwehla kwe-AR kumaseli omhlaza wesibeletho. I-BMC Cancer 2014, 14: 52.
11. UMargel D: iMetformin ukukhusela umdlavuza weprotate: umnxeba wokudibanisa. Eur Urol
2014. doi: 10.1016 / j.eururo.2014.05.012. [Epub ngaphambi kwexesha]
12. UMargel D, i-Urbach DR, i-Lipscombe LL, iBell CM, i-Kulkarni G, i-PC ye-Austin, i-Fleshner
N: Ukusetyenziswa kweMetformin kunye nezobangela zonke zokufa komhlaza wesifo somhlaza
phakathi kwamadoda anesifo seswekile. J Clin Oncol 2013, 31:3069�3075.
13. UTeng CH: I-Metformin inciphisa kakhulu ingozi yomhlaza wesifo seprotate
Abantu baseTaiwan abanesifo sikashukela se-2. I-Eur J Cancer 2014,
50: 2831-2837.
14. UJoshua AM, uZannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M,
Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A,
Fleshner N, Sweet J, Pollak M: Umqhubi wefestile �ifestile yamathuba�
Ucwaningo lwe-neoadjuvant lwe-metformin kwisifo somhlaza wesi-prostate. Prostate
Umhlaza weProstatic Dis 2014, 17:252�258.
15. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi
D, Pollak M, Lui L, Endt K, Schiess R, R�schoff JH, Cathomas R, Gillessen S:
I-Metformin kwi-Chemotherapy-naive Can resist-resistant Cancer Prostate:
Uvavanyo lweSigaba se-2 saManinzi (SAKK 08/09). I-Eur Urol 2014, 66:468�474.
16. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ,
Amling CL, Cooperberg MR, Moorman PG, Freedland SJ: I-Metformin yenza
ayichaphazeli umngcipheko wokuphindaphinda i-biochemical elandelayo
Iprotatectomy: iziphumo ezivela kwi-SEARCH database. Cancer Cancer
I-Prostatic Dis 2013, 16:391�397.
17. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman
M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK,
I-Faison T, iSherher DS, i-Kautzky-Willer A, iBachmann A, iTewari A, i-Shariat SF:
Umbutho wesifo sikashukela se-mellitus kunye ne-metformin esebenzisa i-biochemical
ukuphindaphinda kwizigulane eziphathwe nge-prostatectomy ephezulu yeprotate
umhlaza. Ihlabathi J Urol 2014, 32:999�1005.
18. UMargel D, u-Urbach D, i-Lipscombe LL, i-Bell CM, i-Kulkarni G, i-PC ye-Austin, i-Fleshner
N: Umphakathi phakathi kokusetyenziswa kwe-metformin kunye nomngcipheko womhlaza wesibeletho kunye
ibakala layo. J Natl Cancer Inst 2013, 105:1123�1131.
19. UFranciosi M, uLucisano G, i-Lapice E, iStrippoli GF, uPellegrini F, iNicolucci A:
I-Metformin unyango kunye nomngcipheko womhlaza kwizigulane ezine-2 yeswekile:
uhlolo oluhlelekile. I-PLoS enye ye-2013, i-8: e71583.
20. I-Kaushik D, uKarnes RJ, uEisenberg MS, uRangel LJ, uCarlson RE, uBergstralh EJ:
Impembelelo ye-metformin kwimiphumo yomhlaza wesibeletho emva kokugqithisa
iprostatectomy. Urol Oncol 2014, 32:43 e41�47.
21. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L: Ukusetyenziswa kwe-metformin
izigulane ezinomdlavuza wesibeleko kunye nobungozi bokufa. Cancer Epidemiol
Biomarkers Prev 2014, 23:2111�2118.
22. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K,
I-Sacerdote C, iAshby D, iVineis P, iTzoulaki I, i-Ioannidis JP: I-Metformin ayifuni
zichaphazela ingozi yomhlaza: isifundo seqela kwi-UK Clinical Practice Research
I-Datalink ihlalutya njengolu vavanyo lokufuna ukunyanga. Uncedo lweSwekile 2014,
37: 2522-2532.
23. U-Levine ME, uSuarez JA, uBrhorhorst S, uBalasubramanian P, uCheng CW, uMadiya F,
I-Fontana L, iMolela MG, iGuevara-Aguirre J, Wan J, i-Passarino G, i-Kennedy BK, i-
Wei M, Cohen P, i-Crimmins EM, i-Longo VD: Ukuxhamla kweprotheni ephantsi idibaniswa
kunye nokunciphisa okukhulu kwi-IGF-1, umhlaza kunye nokufa kwabantu bonke kwi-65
kunye nabemi abancinci kodwa ababadala. I-Cell Metab 2014, 19:407�417.
24. USolon-Biet SM, uMcMahon AC, uBallard JW, uRohohonen K, Wu LE, uCogger VC,
I-Warren A, i-Huang X, i-Photoud N, iMelvin RG, i-Gokarn R, i-Khalil M, i-Turner N,
Cooney GJ, uSinclair DA, uRaubenheimer D, Le Couteur DG, uSimpson SJ:
Umlinganiselo wama-macronutrients, kungekhona i-caloric intake, ifuna i-cardiometabolic
impilo, ukuguga, kunye nokuphila ixesha elide kwiimvumi ezondla i-libitum. Cell Metab 2014,
19: 418-430.
25. Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM:
Ukungena kwenyama, intlanzi, iinkukhu, kunye namaqanda kunye nomngcipheko womhlaza wesibeletho
ukuqhubela phambili. Am J Clin Nutr 2010, 91:712-721.
26. UJoshi AD, uJohn EM, uKoo J, i-Ingles SA, i-Stern MC: Ukutya kweentlanzi, ukupheka
izenzo kunye nomngcipheko womhlaza wesibeletho: iziphumo ezivela kwiintlanga ezahlukeneyo
isifundo solawulo. Ulawulo lwe-Cancer Causes Control 2012, 23:405�420.
27. UJoshi AD, uCorral R, uCatsburg C, uLebinger JP, uKoo J, uJohn EM, i-Ingles SA,
I-Stern MC: inyama ebomvu neenkukhu, iindlela zokupheka, ukukhuselwa komzimba
kunye nomngcipheko womhlaza wedlala lesinyi: iziphumo ezivela kulawulo lwezizwe ezininzi
funda. Carcinogenesis 2012, 33:2108�2118.
28. I-Catsburg C, uJoshi AD, uCorral R, uLebinger JP, uKoo J, uJohn EM, i-Ingles SA,
I-Stern MC: I-polymorphisms kwi-enzyme ye-carcinogen enzymes, intlanzi
ukuthatha, kunye nomngcipheko womhlaza wedlala lesinyi. ICarcinogenesis 2012, 33:1352�1359.
29. UPettersson A, uKasperzyk JL, uKenfield SA, u-Richman EL, uKhan JM, uWillett WC,
Stampfer MJ, Mucci LA, Giovannucci EL: Ubisi kunye nokusetyenziswa kotywala
phakathi kwabantu abanomdlavuza wesibeletho kunye nomngcipheko we-metastase kunye ne-prostate
ukufa komhlaza. Cancer Epidemiol Biomarkers Prev 2012, 21:428�436.
30. Deneo-Pellegrini H, uRonco AL, De Stefani E, iBoffetta P, Correa P,
I-Mendilaharsu M, i-Acosta G: Amaqela okutya kunye nomngcipheko womhlaza wesibeletho: a
Isifundo solawulo lwetyala eUruguay. Ulawulo lwe-Cancer Causes Control 2012, 23:1031�1038.
31. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN:
I-calcium, i-vitamin D, kunye nomngcipheko wobisi kunye neengcambu zomhlaza wesibeletho:
Uphononongo lwamaQela aManyeneyo. Ndingu J Epidemiol 2007, 166:1259-1269.
32. Ingoma Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ,
Giovannucci E, Pollak M, Liu S, Ma J: Ubisi lobisi bonke obunxilisayo ludibene
i-prostate-specific mortal among the doctors of US. J Nutr Feb
2013, 143:189�196.
33. Young NJ, Metcalfe C, Gunnell D, Rowlands MA, Lane JA, Gilbert R, Avery
KN, Davis M, Neal DE, Hamdy FC, uDonovan J, uMartin RM, uHolly JM: I-crosssectional
Uhlalutyo lombutho phakathi kokutya kunye nokukhula okufana ne-insulin
i-IGF) -I, i-IGF-II, iprotheni ebophayo ye-IGF (i-IGFBP) -2, kunye ne-IGFBP-3 kumadoda
eUnited Kingdom. Ulawulo lwe-Cancer Causes Control 2012, 23:907�917.
34. Christensen MJ, Quiner TE, Nakken HL, Lephart ED, Eggett DL, Urie PM:
Imiphumo yokudibanisa ye-soy yokutya kunye ne-methylselenocysteine kwimouse
imodeli yomhlaza wesibeleko. Prostate 2013, 73:986-995.
35. Bosland MC, uKato I, Zeleniuch-Jacquotte A, Schmoll J, Enk Rueter E,
Melamed J, Kong MX, Macias V, Kajdacsy-Balla A, Lumey LH, Xie H, Gao W,
Walden P, Lepor H, Taneja SS, Randolph C, Schlicht MJ, Meserve-Watanabe
H, iDataton RJ, Davies JA: Impembelelo yeprotheni ye-soy yodwa isongezelelo
ukuphindaphinda komdlavuza weprotate emva kwesifo se-prostatectomy: a
uvavanyo olungenamkhethe. JAMA 2013, 310:170�178.
36. Chiyomaru T, Yamamura S, Fukuhara S, Yoshino H, Kinoshita T, Majid S, Saini
S, Tshintsha I, Tanaka Y, Enokida H, Seki N, Nakagawa M, Dahiya R: Genistein
inqanda ukukhula komhlaza wesifo somhlaza ngokunyusa i-miR-34a kunye ne-oncogenic
HOTAIR. I-PLoS enye ye-2013, i-8: e70372.
37. Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A, Ritenour C, Wang YA, Kucuk
O, Wu D: U-Genistein ukwandisa ukuphumelela kwe-cabazitaxel chemotherapy
kwiiseli zomhlaza zesifo seprotate ezinqandekile. Iprostate 2013,
73:1681, 1689.38. van Die MD, Bone KM, Williams SG, Pirotta MV: isoflavones yesoya kunye nesoya kwi
Umhlaza wesifo seprotate: uhlolo olusisiseko kunye nokuhlaziywa kweemeta ze-randomized
izilingo ezilawulwayo. BJU Int 2014, 113:E119�E130.
39. Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, iTrasher JB,
I-Kambhampati S, uKeighley J, UVan Veldhuizen P: Ixesha elifutshane le soy isoflavone
ukungenelela kwizigulane ezineengxaki zomhlaza wesibeletho: i-randomized,
ilingo elilawulwa yi-placebo. I-PLoS enye ye-2013, i-8: e68331.
40. I-Pavese JM, uKrishna SN, uBerggan RC: U-Genistein uvimbela i-prostate yabantu
umhlaza wesifo somhlaza, ukuhlasela, kunye ne-metastasis. Am J Clin Nutrition 2014,
100:431S�436S.
41. U-Gonzalez-Menendez P, uHevia D, uRodriguez-Garcia A, uMayo JC, uSainz RM:
Ummiselo we-GLUT wokuthutha nge-flavonoids kwi-androgen-sensitive and
-iiseli zomhlaza wedlala lesinyi. I-Endocrinology 2014, 155:3238�3250.
42. Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Dahiya R:
UGenistein uhlawula i-onco-miR-1260b kwaye uyaphakamisa i-sFRP1 kwaye
Smad4 nge-demethylation kunye ne-histone yokuguqula umhlaza wesibeletho
iiseli. Br J Cancer 2014, 110:1645�1654.
43. I-Handayani R, i-Rice L, iCui Y, i-Medrano TA, i-Samedi VG, i-Baker HV, i-Szabo NJ, i-
Shiverick KT: I-Soy isoflavones ishintshana ukubonakalisa iigeni ezidibeneyo
ukuqhubeka komhlaza, kubandakanya i-interleukin-8, kwi-androgen-emele
I-PC-3 yeeseli zomhlaza womntu we-prostate. J Nutr 2006, 136:75�82.
44. I-Travis RC, i-Allen NE, i-Appleby PN, ixabiso le-A, i-Kaaks R, i-Chang-Claude J, i-Boeing H, i-
Aleksandrova K, Tjânneland A, Johnsen NF, Overvad K, Ramn Quir's J,
Gonzlez CA, Molina-Montes E, S�nchez MJ, Larra�aga N, Castao JM,
Ardanaz E, Khaw KT, Wareham N, Trichopoulou A, Karapetyan T, Rafnsson
SB, Palli D, Krogh V, Tumino R, Vineis P, Bueno-de-Mesquita HB, Stattin P,
UJohansson M, et al al: I-Prediagnostic concentrations of plasma genistein kunye
Ingozi yomhlaza wesifo seprotate kwi-1,605 amadoda ene-prostate cancer kunye ne-1,697
uhambelana nabaphathi be-EPIC. I-Caus Causes Control 2012,
23: 1163-1171.
45. Jackson MD, McFarlane-Anderson ND, uSimon GA, uBennett FI, Walker SP:
I-urinary phytoestrogens kunye nomngcipheko womhlaza wesibeletho kumadoda aseJamaican.
Ulawulo lwe-Cancer Causes Control 2010, 21:2249�2257.
46. Lazarevic B, Hammarstr�m C, Yang J, Ramberg H, Diep LM, Karlsen SJ,
Kucuk O, Saatcioglu F, Task�n KA, Svindland A: Iziphumo zexesha elifutshane
i-genistein yokungenelela kwiprotate biomarker ibonakaliso kwizigulane ezinalo
umdlavuza weprotate wangaphambili ngaphambi kokuba i-prostatectomy enkulu. Br J Nutritional 2012,
108: 2138-2147.
47. Epstein MM, uKasperzyk JL, uMucci LA, Giovannucci E, iNtengo A, i-Wolk A,
H�kansson N, Fall K, Andersson SO, Andr�n O: Ukutya okunamafutha e-asidi kunye
Umdlavuza wesibeletho kwi-Orebro County, eSweden. Am J Epidemiol 2012,
176: 240-252.
48. UKobayashi N, Barnard RJ, Uthi J, uHong-Gonzalez J, uCorman DM, Ku M,
I-Doan NB, i-Gui D, i-Elashoff D, i-Cohen P, i-Aronson i-WJ: Umphumo wesondlo se-fat fat
uphuhliso lomhlaza wesibeletho kunye ne-Akt phosphorylation kwi-Hi-Myc
imodeli yemouse eguquguqukayo. Umhlaza Res 2008, 68:3066�3073.
49. NgoO, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali
YI, Heber D, Aronson WJ: Imiphumo ye-fat-fat-fat diet on human
I-LAPC-4 umdlavuza wesifo seprotate xenografts kwi-immunodeficient ehlanganisiweyo
iigundane kunye ne-insulin-efana nokukhula kwezinto. Isifo seKliniki yeRC 2003,
9: 2734-2743.
50. Huang M, Narita S, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y,
UTuchiya N, Habuchi T: Ukutya okunamafutha aphezulu kukuphucisa ukwanda kwamanzi
iiseli zomhlaza zesifo seprotate kwaye yenza i-MCP-1 / CCR2 isayinwe. Iprostate 2012,
72: 1779-1788.
51. Chang SN, Han J, Abdelkader TS, Kim TH, Lee JM, Ingoma J, Kim KS, Park JH,
I-Park JH: Ukutya kwezilwanyana eziphakamileyo kukunyusa ukwandisa umdlavuza weprotate
kunye nokunciphisa i-glutathione peroxidase ibinzana le-3 kumazinga okuqala
TRAMP iimpuku. Prostate 2014, 74:1266-1277.
52. I-Bidoli E, iTalamini R, iBosetti C, i-Negri E, i-Maruzzi D, iMontella M, i- Franceschi S, i-
I-Vecchia C: i-macronutrients, i-fatty acids, i-cholesterol kunye nomdlavuza wesi-prostate
ingozi. Ann Oncol 2005, 16:152�157.
53. Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN: I-Fat kunye nenyama
ingozi yomhlaza wesifo seprotate: isifundo seqela lamaqela amaninzi. Int J Cancer
2007, 121:1339�1345.
54. Wallstrom P, uBjartell A, Gullberg B, Olsson H, Wirfalt E: Ufuna ukufunda
kumafutha atyayo kunye nesiganeko somhlaza wesibeletho (i-Malmo, eSweden).
Ulawulo lwe-Cancer Causes Control 2007, 18:1107�1121.
55. Crowe FL, i-TJ eyintloko, i-Appleby PN, i-Travis RC, i-Overvad K, i-Jakobsen MU, i-
Johnsen NF, Tj�nneland A, Linseisen J, Rohrmann S, Boeing H, Pischon T,
Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Palli D, Tumino R,
UKrogh V, uBueno-de-Mesquita HB, i-Kiemeney LA, i-Chirlaque MD, i-Ardanaz E,
S�nchez MJ, Larra�aga N, Gonzlez CA, Quir’s JR, Manjer J, Wirf�lt E, Stattin
P, et al: Ukutya okunamafutha okutya kunye nomngcipheko womhlaza wesibeletho kwiYurophu
Uphando olujoliswe kwiCanscer and Nutrition. Am J Clin Nutrition 2008,
87: 1405-1413.
56. Ohwaki K, Endo F, Kachi Y, Hattori K, Muraishi O, Nishikitani M, Yano E:
Ubudlelwane phakathi kwezinto zokutya kunye ne-prostate-specific antigen
amadoda asempilweni. Urol Int 2012, 89:270�274.
57. Bassett JK, Severi G, Hodge AM, MacInnis RJ, Gibson RA, Hopper JL,
IsiNgesi DR, iGiles GG: I-Plasma phospholipid i-fatty acids, i-fatty acids acids
kunye nobungozi bomhlaza wedlala lobudoda. Int J Cancer 2013, 133:1882�1891.
58. Richman EL, uKenfield SA, Chavarro JE, Stampfer MJ, Giovannucci EL, Willett
I-WC, i-Chan JM: I-Fat yidla emva kokuxilongwa kunye nomngcipheko wesifo somhlaza wesifo somhlaza
kunye nokufa okubangelwa yiyo yonke into. JAMA Intern Med 2013, 173:1318�1326.
59. CD eWilliams, iWhiteley BM, iHoyo C, i-Grant DJ, i-Iraggi JD, i-Newman KA, i-Gerber
L, Taylor LA, McKeever MG, Freedland SJ: Umlinganiselo ophezulu we-n-6 / n-3
i-polyunsaturated fatty acids ihambelana nobungozi obuninzi beprotate
umhlaza. Nutr Res 2011, 31:1�8.
60. Chua ME, iSoo MC, iSorongon MC, iDy JS: Ulwalamano lokutya lokutya
i-omega-3 kunye ne-omega-6 i-fatty iyenomngcipheko womhlaza wesibeletho
uphuhliso: uhlalutyo lwe-meta-uphando lweziphumo kunye nokuphononongwa
uncwadi. I-prostate Cancer 2012, 2012: 826254.
61. I-Berquin IM, u-Edwards IJ, uKridel SJ, uKhen YQ: I-Polyunsaturated fatty acid
i-metabolism kumhlaza we-prostate. Umhlaza weMetastasis Rev 2011, 30:295�309.
62. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu
B, Grey A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Wathi
J, Cohen P, Galet C: IsiGaba sesi-II esilindele ukuhlolwa kwe-fat fat fat
kunye ne-oil oil supplementation kwindoda ejongene ne-prostatectomy enkulu.
Cancer Prev Res (Phila) 2011, 4:2062�2071.
63. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S: I-Arachidonic acid
ivuselela i-phosphatidylinositol i-3-kinase ukubonisa kwaye ivuselele i-gene
ukubonakaliswa kumhlaza we-prostate. Umhlaza Res 2006, 66:1427�1433.
64. Moreel X, Allaire J, Leger C, Caron A, Labonte ME, uLamarche B, uJulien P,
I-Desmeules P, T�tu B, Fradet V: Prostatic kunye ne-dietary omega-3 fatty acids
kunye nokuqhubeka komhlaza wesifo seprotate ngexesha lokujonga iliso. Cancer Prev
Res (Phila) 2014, 7:766�776.
65. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D,
Igosa W, uDennison A: Impembelelo ye-omega-3 FAs kwi-tumor angiogenesis
kunye namandla abo onyango. Eur J Cancer 2009, 45:2077�2086.
66. Gu Z, Suburu J, Chen H, Chen YQ: Iinkqubo ze-omega-3 i-polyunsaturated
amanqindi e-fatty in prostate prevention prevention. I-Biomed Res Int 2013, 2013: 824563.
67. ULloyd JC, EMasko EM, Wu C, Keenan MM, uPilla DM, Aronson WJ, Chi JT,
I-Freedland SJ: Ioli yeentlanzi iyancipha umhlaza wesifo somhlaza wesifo sogqirha xenograft ukukhula
amanye amafutha okutya kwaye anxulumene nokunciphisa i-mitochondrial kunye
i-insulin yomzila wesigidi. Iprostate Cancer Prostatic Dis 2013,
16: 285-291.
68. UWilliam CM, Burdge G: I-long-chain n-3 PUFA: isityalo v.
Proc Nutr Soc 2006, 65:42�50.
69. Galet C, Gollapudi K, Stepan S, Byrd JB, Henning SM, Grogan T, Elashoff
D, uHeber D, wathi J, Cohen P, Aronson WJ: Impembelelo yokutya kweoli yeentlanzi ezincinci
kwi-eicosanoids yeproinflammatory kunye nomlinganiselo wokuqhubela phambili kweseli
amadoda aphantsi kweprostatectomy enkulu. I-Cancer Prev Res (Phila) 2014,
7: 97-104.
70. Bosire C, uSampampfer MJ, uAstern AF, iPark Y, Kirkpatrick SI, ChiVE SE, Hollenbeck
I-AR, i-Aids J: Iipatheni zokutya ezisekelwe kwikhompyutheni kunye nomngcipheko womhlaza wesibeletho
kwi-NIH-AARP yokutya kunye nesifundo sezempilo. Ndingu J Epidemiol 2013, 177:504�513.
71. Aronson WJ, Barnard RJ, Freedland SJ, uHenning S, uElashoff D, Jardack PM,
Cohen P, uHeber D, uKobayashi N: Ukukhula okuvimbela ukunyusa kwe-fat fat
kwiiseli zomhlaza wesifo seprotate: iziphumo zendlela yokutya, okungeyona nto
ulingo longenelelo kumadoda anomhlaza wedlala lesinyi. J Urol 2010, 183:345�350.
72. Brouwer IA, iGeleijnse JM, Klaasen VM, Smit LA, Giltay EJ, de Goede J,
I-Heijboer AC, i-Kromhout D, i-Katan MB: Impembelelo ye-alpha linolenic acid
ukuxhaswa kwi-serum prostate ethile ye-antigen (PSA): iziphumo ezivela
ityala le-alpha omega. I-PLoS enye ye-2013, i-8: e81519.
73. Chua ME, Sio MC, Sorongon MC, Morales ML Jr: Ukufaneleka kwe-serum
amanqanaba omnxeba omde omega-3 i-polyunsaturated fatty acids kunye neprotate
ingozi yomhlaza: Uhlalutyo lwemeta. Ngaba urol Assoc J 2013, 7:E333�E343.
74. Y, S, Lee, Lee SY, Lee HJ, Shao T, Ingoma B, Cheng L, Masterson TA, Liu X,
I-Ratliff TL, i-Cheng JX: Ukuqokelela kwe-Cholesteryl ester eyenziwa yi-PTEN ukulahleka
kunye nokusetyenziswa kwe-PI3K / AKT phantsi komdlavuza wesifo somntu
ubundlongondlongo. I-Cell Metab 2014, 19:393�406.
75. Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB: I-Cholesterolinduced
Ukusebenza kwe-TRPM7 ilawula ukusabalala kweseli, ukufuduka,
kunye nokusebenza kweeseli zomzimba zengxowankulu. Biochim Biophys Acta 1843,
2014: 1839-1850.
76. Murai T: I-cholesterol yehla: indima ekukhuselweni komhlaza kunye nonyango.
I-Biol Chem 2014. doi: 10.1515 / hsz-2014-0194. [Epub ngaphambi kwexesha]
77. UZhuang L, uKim J, uAdam RM, uSolomon KR, uFreeman MR: Cholesterol
ukujolisa ukuguqula i-lipid raft kunye nokuhlala kwintsholongwane yomhlaza wesibeletho
iiseli kunye xenografts. J Clin Invest 2005, 115:959�968.
78. I-Mostaghel EA, uSolomon KR, uPelton K, Freeman MR, i-Montgomery RB:
Impembelelo yokujikeleza amazinga e-cholesterol ekukhuleni nase-intratumoral
kunye ne-androgen ingxube yee-tumor tumors. PLoS One 2012,
7: e30062.
79. I-Morote J, iCelma A, i-Planas J, i-Placer J, i-Torres I, u-Olivan M, uCarles J,
URevent's J, unodoli A: Indima ye-serum cholesterol kunye nokusetyenziswa kwe-statin emngciphekweni woku
ukufumanisa umdlavuza weprotate kunye nokuxhalaba. Int J Mol Sci 2014,
15: 13615-13623.
80. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK,
I-Amling CL, i-Freedland SJ: Ukusetyenziswa kwe-statinative kunye nomngcipheko we-biochemical
ukuphindaphinda emva kweprotectomyomy enkulu: iziphumo ezivela kwi-Shared
Isibhedlele seNgcaciso yeSifo seKhansela (SEARCH) se-Equal Access. BJU Int 2014,
114: 661-666.
81. UJespersen CG, uNorgaard M, Friis S, Skriver C, uBorre M: Ukusetyenziswa kweStatin kunye nobungozi
Umhlaza wedlala lobudoda: Uphononongo olusekwe kuluntu lwaseDenmark,
1997-2010. Umhlaza Epidemiol 2014, 38:42�47.
82. CD ye-Meyers, iKashyap ML: Ukuphakama kwe-Pharmacologic ye-high-density
lipoproteins: ukuqonda kwangoku kwindlela yokusebenza kunye ne-atherosclerosis
ukhuselo. Curr Opin Cardiol 2004, 19:366�373.
83. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR: Ii-lipoproteins eziphezulu
(HDL) ukuphazamisa indlela yokutshintshela i-sphingosine kinase. A kwenzeka
indlela yokukhusela i-atherosclerosis yi-HDL. J Biol Chem
1999, 274:33143�33147.
84. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: Ukuphakama okukhulu
i-lipoprotein kunye nomhlaza wesifo seprotate: isicatshulwa. J Epidemiol 2013,
23: 313-319.
85. Soni MG, eTrandmond TS, Miller ER 3rd, i-Spriggs T, iBendich A, i-Omaye ST:
Ukukhuselwa kwamavithamini kunye neemaminerali: iingxabano kunye nombono. I toxicol
Sci 2010, 118:348�355.
86. I-Neuhouser ML, uBarnett MJ, uKristal AR, u-Ambrosone CB, uKumkani I, uT Thornquist M,
I-Goodman G: (n-6) Ukwandiswa kwe-PUFA kunye nokutya kweebisi kunciphisa i-prostate
ingozi yomhlaza kubantu abatshaya kakhulu. J Nutr 2007, 137:1821-1827.
87. Karppi J, Kurl S, Laukkanen JA, Kauhanen J: I-betum-carotene ngokuphathelele
umngcipheko womhlaza wesibeletho: i-Kuopio Ischemic Heart Heart Risk
Isifundo. Nutr Cancer 2012, 64:361�367.
88. UMargalit DN, uKasperzyk JL, uMartin NE, uSesso HD, uGaanoano JM, MaJ, uStampfer
UMJ, uMucci LA: I-Beta-carotene esebenzisa i-antioxidant ngexesha lokunyanga kwamayeza
kunye nesiphumo somhlaza wedlala lesidlala kwiSifundo seMpilo yooGqirha. Int J Radiat
I-Oncol Biol Phys 2012, 83:28�32.
89. Roswall N, uLarsen SB, Friis S, Outzen M, Olsen A, Christensen J, Dragsted LO,
Tj�nneland A: Ukuthathwa kwe-micronutrient kunye nomngcipheko womhlaza wedlala lesinyi kwi-
iqela labantu abaneminyaka ephakathi, amadoda aseDanish. I-Caus Causes Control 2013,
24: 1129-1135.
90. Gilbert R, Metcalfe C, Fraser WD, uDonovan J, Hamdy F, Neal DE, uLane JA,
UMartin RM: Amashishini okujikeleza i-retinol, i-vitamin E, ne-1,25-
i-dihydroxyvitamin D ene-prostate diagnostic, isigaba kunye nebanga.
Ulawulo lwe-Cancer Causes Control 2012, 23:1865�1873.
91. Bistulfi G, Foster BA, Karasik E, Gillard B, Miecznikowski J, Dhiman VK,
I-Smiraglia DJ: Ukusilela kwintlobo yesondlo kubangela ukuqhubela phambili komhlaza wesifo somhlaza
kwimodeli yeTRAMP. Cancer Prev Res (Phila) 2011, 4:1825�1834.
92. I-Collin SM: I-Folate kunye ne-B12 kumdlavuza wesibeletho. Adv Clin Chem 2013,
60: 1-63.
93. Tio M, Andrici J, Cox MR, Eslick GD: I-Folate ifake kunye nomngcipheko we-prostate
umhlaza: uhlolo oluchanekileyo kunye nohlalutyo lweemeta. Prostate Cancer Prostatic
Dis 2014, 17:213-219.
94. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J,
Manson JE, Hankey GJ, Spence JD, Galan P, B�naa KH, Jamison R, Gaziano
JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland
PM, uBennett D, u-Collins R, uPeto R, B-I-Vitamin Treatment Trialists 'Ukusebenzisana:
Iimpembelelo zokuncedisa i-folic acid kwi-overall and site-specific cancer
iziganeko ngexesha leemvavanyo ezilandelelisiweyo: i-meta-analysis of data kwi-50,000
abantu ngabanye. Lancet 2013, 381:1029�1036.
95. Verhage BA, Cremers P, Schouten LJ, Goldbohm RA, van den Brandt PA:
Isondlo sesidlo kunye ne-vitamers kunye nomngcipheko womhlaza wesibeletho
Isifundo seNkokheli yamaNetherlands. I-Caus Causes Control 2012,
23: 2003-2011.
96. Tavani A, Malerba S, Pelucchi C, Dal Maso L, Zucchetto A, Serraino D, Levi F,
UMontella M, uFranceschi S, i-Zambon A, iLa Vecchia C: Ukutya kunye nokutya
umngcipheko womhlaza kuthungelwano lwezifundo zolawulo lwetyala. Ann Oncol 2012,
23: 2737-2742.
97. Dora Moreira, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Ukulinganisa
CL, i-Freedland SJ: I-high serum folate idibene nehliswe
ukuphindaphinda kwe-biochemical emva kwe-prostatectomy enkulu: iziphumo ezivela kuyo
KHANGELA uvimba weenkcukacha. Int Braz J Urol 2013, 39:312�318. ingxoxo 319.
98. Han YY, Ingoma JY, Talbott EO: I-Serum folate kunye ne-prostate-specific antigen
iunited States. Ulawulo lweCancer Causes Control 2013, 24:1595�1604.
99. URycyna KJ, u-Bacich DJ, u-O'Keefe DS: Ukuchasana neendima ze-prostate
umhlaza. Urology 2013, 82:1197�1203.
100. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE,
I-Fraser WD, iSterne JA, iMetcalfe: Iinkampani zokujikeleza kunye nezondlo
ivithamin D enobungozi bomhlaza wedlala lobudoda: uphononongo olucwangcisiweyo kunye nethamo�
impendulo meta-uhlalutyo. Ulawulo lwe-Cancer Causes Control 2011, 22:319�340.
101. Schenk JM, Kuze kube yi CA, iTangen CM, Goodman PJ, Ingoma X, iTorkko KC, Kristal AR,
I-Peters U, i-Neuhouser ML: I-Serum 25-hydroxyvitamin d kunye noku
Umngcipheko womhlaza wesifo seprotate: iziphumo ezivela kwi-Prostate Cancer Prevention Trial.
Cancer Epidemiol Biomarkers Prev 2014, 23:1484�1493.
102. I-Schwartz GG: I-Vitamin D, egazini kunye nomngcipheko womhlaza wesibeletho: izifundo
ukusuka kwiSelenium kunye neVitamin E yeCrown Prevention Trial kunye
Uvavanyo lokuLungisa umdlavuza weCarstate. I-Cancer Epidemiol Biomarkers I-2014,
23: 1447-1449.
103. Giangreco AA, Vaishnav A, Wagner D, Finelli A, Nenyama, N, Van der Kwast T,
Ubomi R, Nonn L: I-microRNA, i-miR-100 kunye ne -125b,
ilawulwa yi-1,25-dihydroxyvitamin D kwiiseli eziphambili ze-prostate kwaye
izicubu zesigulana. Cancer Prev Res (Phila) 2013, 6:483�494.
104. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S:
Ukuxhaswa kwe-Vitamin D3, umdlavuza we-prostate umngcipheko, kunye nempilo
iyantlukwano. J Steroid Biochem Mol Biol 2013, 136:233�237.
105. Sha J, Pan J, Ping P, Xuan H, Li D, Bo J, Liu D, Huang Y: I-Synergistic effect
kunye nendlela yevithamini A kunye ne-vitamin D ekunciphiseni iipoptosis
iiseli zomhlaza wedlala lesinyi. Mol Biol Rep 2013, 40:2763�2768.
106. UCandler PD, uGivanvanucci EL, Scott JB, Bennett GG, Ng K, Chan AT, Hollis
BW, Emmons KM, Fuchs CS, Drake BF: Umbutho we-Null phakathi kweVitamin D
kunye namanqanaba e-PSA phakathi kwamadoda amnyama kwilingo lokuxhaswa kwe-Vitamin D.
Cancer Epidemiol Biomarkers Prev 2014, 23:1944�1947.
107. I-Skaaby T, i-Husemoen LL, i-Thuesen BH, i-Pisinger C, i-Jorgensen, i-Roswall N, i-
ULarsen SC, uLinneberg A: Uvavanyo olusisiseko lwabantu
ubudlelwane phakathi kwamanqanaba e-serum 25-hydroxyvitamin-D kunye
iziganeko ezithile zeentsholongwane zomhlaza. I-Cancer Epidemiol Biomarkers Ngaphambili
2014, 23:1220�1229.
108. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL: Amanqanaba okujikeleza
I-25-hydroxyvitamin D kunye nomhlaza wesibeletho. Cancer Epidemiol
2013, 37:666�670.
109. Wong YY, Hyde Z, McCaul KA, Yeap BB, Golledge J, Hankey GJ, Flicker L:
Kwamadoda amadala, i-plasma ephantsi i-25-hydroxyvitamin D idibene nayo
kuncitshiswa kwimeko yeprotrate, kodwa kungekhona umdlavuza omnyama okanye umdlavuza.
I-PLoS enye ye-2014, i-9: e99954.
110. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z: Uhlobo oluhle
phakathi kokujikeleza amazinga e-25-hydroxyvitamin D kunye nomngcipheko womhlaza wesifo somhlaza:
iziphumo ezitsha kwi-meta-analysis analysis. J Cancer Res Clin I-Oncol
2014, 140:1465�1477.
111. Meyer HE, uRobsahm TE, uBjorge T, Brustad M, Blomhoff R: I-Vitamin D, ixesha,
kunye nomngcipheko womhlaza wedlala lesidlala: isifundo solawulo esifakwe ngaphakathi
Izifundo zezempilo zaseNorway. Am J Clin Nutr 2013, 97:147-154.
112. I-Kristal AR, kufike C, Ingoma X, iTangen CM, Goodman PJ, Neuhauser ML, Schenk
JM, Thompson IM, Meyskens FL Jr, Goodman GE, iLM Minasian, iParnes HL,
I-Klein EA: I-Plasma vitamin D kunye nomngcipheko womhlaza wesifo seprotate: iziphumo ezivela kuyo
I-Selenium kunye ne-Vitamin E yokuLungisa iCarcer Prevention. Cancer Epidemiol
Biomarkers Prev 2014, 23:1494�1504.
113. Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D:
Ukujikeleza i-25-hydroxyvitamin D, iiprotheni ezibopha i-vitamin D kunye nobungozi
umhlaza wedlala lesinyi. Int J Cancer 2013, 132:2940�2947.
114. Guo Z, Wen J, Kan Q, Huang S, Liu X, Sun N, Li Z: Ukungabikho kombutho
phakathi kwe-vitamin D receptor gene FokI kunye ne-BsmI polymorphisms kunye �nomngcipheko womhlaza weprostate: uhlalutyo oluhlaziyiweyo olubandakanya izifundo ezingama-21,756. I-Tumor Biol 2013, 34:3189�3200115. Wang L, Sesso HD, Glynn RJ, Christen WG, Bubes V, Manson JE, Buring JE,
IGaanoano JM: Ukongezwa kwe-Vitamin E no-C nomngcipheko womhlaza kumadoda:
ulandelelwano lwasemva kovavanyo kooGqirha� iSifundo seMpilo II solingo olungenamkhethe.
Am J Clin Nutr 2014, 100:915-923.
116. Virtamo J, Taylor PR, Kontto J, Mannisto S, Utriainen M, Weinstein SJ,
Huttunen J, Albanes D: Iimpembelelo ze-alpha-tocopherol kunye ne-beta-carotene
ukuxhaswa komdlavuza kunye nokufa: i-18-nyaka
ukulandelelwaniswa kwe-Alpha-tocopherol, i-Beta-carotene
Uphononongo loThintelo loMhlaza. Int J Cancer 2014, 135:178�185.
117. I-Basu A, Imrhan V: I-Vitamin E kunye nomhlaza wesifo seprotate: i-vitamin E ilandele i-a
i-agent ye-chemopreventive ephezulu? Nutr Rev 2005, 63:247�251.
118. Lawson KA, Wright ME, i-Subar A, i-Mouw T, i-Hollenbeck A, iSchatzkin A,
I-Leitzmann MF: Ukusetyenziswa kwe-Multivitamin kunye nomngcipheko wesifo somhlaza wesibeletho
Izikolo zeSizwe zezeMpilo-I-AAR Diet and Study Study. J Natl Cancer
Ngo-2007, 99:754-764.
119. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML,
UFeigelson HS, uThun MJ: I-American Cancer Society I-Prevention Cancer
Isifundo II Iqela leZondlo: isiseko, isicwangciso sokufunda, kunye nesiseko
iimpawu. Umhlaza 2002, 94:2490�2501.
120. I-Weinstein SJ, uPeter U, uAhn J, iM MD ye-Friesen, uRiboli E, iHayes RB, i-Albanes D:
I-serum i-alpha-tocopherol kunye neembalo ze-gamma-tocopherol kunye
Umngcipheko womhlaza wedlala lobudoda kuvavanyo lwe-PLCO yokuHlola: ulawulo olufakwe kwindlwane
kufunda. I-PLoS enye ye-2012, i-7: e40204.
121. Cui R, Liu ZQ, Xu Q: I-alpha-tocopherol yegazi, amanqanaba e-gamma-tocopherol
kunye nomngcipheko womhlaza wesifo seprotate: uhlalutyo lwe-meta-uphando lwabafundi.
I-PLoS enye ye-2014, i-9: e93044.
122. JM omkhulu, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, Chanock S,
I-Albanes D: Iinguqu ze-Genetic ezibonisa izinga eliphezulu le-vitamin e kumadoda
inxulumene nomngcipheko omncinci womhlaza wesibeletho. I-J Nutryi Meyi 2014,
144: 729-733.
123. Klein EA, Thompson IM Jr, CM Tangen, Crowley JJ, uLucia MS, Goodman PJ,
IMinasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther
PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE,
I-Meyskens FL Jr, i-Baker LH: I-Vitamin E kunye nomngcipheko womhlaza wesibeletho: i
I-Selenium kunye ne-Vitamin E yokuLungisa iCarcer Prevention (SELECT). JAMA 2011,
306: 1549-1556.
124. I-Albanes D, ukuya ku-C, uKlein EA, Goodman PJ, i-Mondul AM, i-Weinstein SJ, i-PR, i-
I-Parnes HL, i-Gaziano JM, iNgoma X, i-Fleshner NE, i-Brown PH, i-Meyskens FL Jr, i-
I-IM IM: I-tocopherols ye-Plasma kunye nomngcipheko womhlaza wesibeletho
I-Selenium kunye ne-Vitamin E yokuLungisa iCarcer Prevention (SELECT). I-Cancer Prev Res
(Phila) 2014, 7:886�895.
125. I-Kristal AR, iDarke AK, i-Morris JS, i-Tangen CM, i-Goodman PJ, i-Thompson IM, i-
I-Meyskens FL Jr, i-Goodman GE, i-LM Minasi, i-Parnes HL, i-Lippman SM, i-
I-Klein EA: Isiseko se-selenium nesimo se-selenium kunye ne-vitamin e
ukuxhaswa kwingozi yomhlaza wesibeletho. I-Natl Cancer Inst 2014,
106: djt456.
126. UJamison JM, uGilloteaux J, iTaper HS, i-Summers JL: Uvavanyo lwe-in vitro
kunye nemisebenzi yokuphikisa i-vitamin C kunye ne-K-3
ngokuchasene nomhlaza womntu wedlala lobudoda. J Nutr 2001, 131:158S�160S.
127. Nimptsch K, uRohrmann S, Kaaks R, Linseisen J: I-vitamin K yokutya
ngokumalunga nomhlaza wesiganeko nokufa: iziphumo ezivela kulo
Iqela laseHeidelberg loPhando loPhando lwaseYurophu
I-Cancer kunye Nondlo (EPIC-Heidelberg). Am J Clin Nutrition 2010,
91: 1348-1358.
128. I-RW, i-Chapman K: Ukuphononongwa ngokuchanekileyo kwesiphumo sokutya kwi-prostate
ukuthintela umhlaza kunye nonyango. J Hum Nutr Diet 2009, 22:187-199.
umbuzo 200�182.
129. Bristow SM, iBolland MJ, i-MacLennan GS, i-Avenell A, iGrey A, iGamble GD, iReid
IR: I-supplementary calcium kunye nomngcipheko womhlaza: uhlalutyo lwe-meta lwe-randomized
izilingo ezilawulwayo. Br J Nutr 2013, 110:1384-1393.
130. CD eWilliams, iWhiteley BM, iHoyo C, i-Grant DJ, i-Schwartz GG, i-Presti JC Jr, i-Iraggi
JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ: Izidlo
calcium kunye nomngcipheko womhlaza weprotate: isifundo solawulo lwetyala phakathi kwe-US
bezilwanyana. I-Chronic Dis 2012, i-9: i-E39.
131. Hori S, Butler E, McLoughlin J: Umhlaza wesifo seprostate kunye nokutya: ukutya kokucinga?
BJU Int 2011, 107:1348�1359.
132. Geybels MS, Verhage BA, van Schooten FJ, Goldbohm RA, van den Brandt
I-PA: Umngcipheko womhlaza we-prostate umngcipheko ngokubhekiselele kumanqanaba e-selenium.
J Natl Cancer Inst 2013, 105:1394�1401.
133. Singh Singh, Agarwal R: I-chemoprevention yomhlaza weprostate yi-sibinin: ibhentshi
ecaleni kwebhedi. Mol Carcinog 2006, 45:436�442.
134. I-H, i-Deep G, i-Agarwal R: Iinkqubo ze-molecular ze-sibinin-mediated
i-chemoprevention yomhlaza ngokugxininisa kakhulu kumhlaza wesibeletho.
I-AAPS J 2013, 15:707�716.
135. I-Ting HJ, Deep G, Jain AK, iCimic A, i-Sirintrapun J, iRomero LM, i-SD ye-Cramer,
I-Agarwal C, i-Agarwal R: I-Silibinin inqanda umdlavuza weprotate
ukwahlukana kwe-fibroblasts engabonakaliyo kwi-fibroblast echaphazeleka ngumhlaza
i-phenotype ngokujolisa kwi-beta2 ye-TGF. Mol Carcinog 2014. i-doi: 10.1002 /
mc.22135. [Epub ngaphambi kwexesha]
136. I-Goel A, i-Aggarwal BB: I-Curcumin, isipayisi segolide esivela kwi-safroni yaseIndiya
i-chemosensitizer kunye ne-radiosensitizer for tumors and chemoprotector kunye
radioprotector amalungu eqhelekileyo. Nutr Cancer 2010, 62:919�930.
137. Khan N, Adhami VM, Mukhtar H: I-apoptosis ngabagulisi bokutya
ukuthintela kunye unyango lomhlaza wesibeletho. I-Endocr Cancer XTUMX,
17:R39.R52.
138. UHeber D: Iipomegranate ellagitannins. Kwi-Herbal Medicine: i-Biomolecular kunye
Izinto zeKliniki. I-2nd edition. Ehlelwe nguBenzie IF, iWachtel-Galor S. Boca
I-Raton, FL: Inkcazo yeCroC; 2011.
139. I-Pantuck AJ, Leppert JT, i-Zomorodian N, i-Aronson W, i-Hong J, i-Barnard RJ, i-
I-Seeram N, Uthande H, Wang H, uElashoff R, Heber D, Aviram M, Ignarro L,
I-Belldegrun A: Isifundo seSigaba II segromegranate ijusi yamadoda ekhulayo
i-anti-anti-specific antigen emva kokuhlinzwa okanye i-radiation ye-prostate
umhlaza. I-Clin Cancer Res 2006, 12: 4018�4026.
140. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton
BR, i-Hertzman BL, i-Efros MD, i-Roper RP, ukuthanda i-HR, i-Carducci MA: i-randomized
Ucwaningo lwesigaba II se-pomegranate kwindoda ekhulayo i-PSA elandelayo
lokuqala unyango lwe-prostate cancer. Prostate Cancer Prostatic Dis
2013, 16:50�55.
141. I-Freedland SJ, iCarducci M, iKroeger N, iCartin A, uRao JY, i-Jin Y, iKerkoutian S, i-
Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y,
I-Heber D, i-Pantuck AJ: Uphando oluphinda luyimpumputhe, olulinganisekanga, olusandululwazi
iziphumo zamathambo zePOMx iipilisi kumadoda anomdlavuza wesibeletho ngaphambili
iprostatectomy enkulu. Cancer Prev Res (Phila) 2013, 6:1120�1127.
142. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM:
I-Green tea i-polyphenol kunye ne-metabolites kwi-tisti ye-prostatectomy:
iziphumo zokuthintela umdlavuza. I-Cancer Prev Res (Phila) 2010,
3: 985-993.
143. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S: I-Green tea
ukusetyenziswa kunye nomngcipheko womhlaza wesibeletho kumadoda aseJapane: umntu ozayo
funda. Am J Epidemiol 2008, 167:71�77.
144. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA: I-Tea
i-polyphenols inciphisa amanqanaba e-serum ye-prostate-specific antigen,
i-hepatocyte growth factor, kunye ne-vascular endothelial growth factor in
izigulane ze-prostate zegciwane kwaye zivimbela ukuveliswa kwe-hepatocyte ukukhula
into kunye ne-vastotic endothelial growth factor in vitro. I-Cancer Prev Res
(Phila) 2009, 2:673�682.
145. I-Bettuzzi S, uBrausi M, uRizzi F, i-Castagnetti G, i-Peracchia G, i-Corti A:
I-Chemoprevention yesifo somhlaza wesibeletho somntu ngokulawulwa ngomlomo
iikatekini ze-green tea kumavolontiya anama-high-grade prostate intraepithelial
i-neoplasia: ingxelo yokuqala evela kwisifundo seminyaka-ye-proof-of-principle.
Umhlaza Res 2006, 66:1234�1240.
146. UFraser SP, uPeter A, uFleming-Jones S, Mukhey D, Djamgoz MB: I-Resveratrol:
iziphumo ezingavimbelayo kwiimpawu zesetragram zeemetastatic kunye ne-vol--ated Na (+)
umsebenzi wesiteshi kumdlavuza we-prostate in vitro. I-Cancer Cancer 2014,
66: 1047-1058.
147. Oskarsson A, Spatafora C, Tringali C, Andersson AO: Ukuvinjelwa kwe-CYP17A1
umsebenzi nge-resveratrol, i-piceatannol, kunye nama-analogs ahlanganisiweyo.
Prostate 2014, 74:839-851.
148. UFerloelo A, uRomero I, uChabrera PM, u-Arance I, Andres G, u-Angulo JC: Iziphumo ze
i-resveratrol kunye nezinye i-polyphenols zewayini ngokusasazeka, i-apoptosis
kunye ne-androgen ye-receptor ibonakaliso kwiiseli ze-LNCaP. Actas Urol Esp Jul-Aug
2014, 38:397�404.
149. Osmond GW, EMasko EM, iTyler DS, i-Freedland SJ, i-Pizzo S: i-In vitro kunye ne-vivo
Uvavanyo lwe-resveratrol kunye ne-3,5-dihydroxy-4?-acetoxy-trans-stilbene
unyango lwe-prostate carcinoma kunye ne-melanoma. J Surg Res
2013, 179:e141�e148.
150. I-Baur JA, i-DA ye-Sinclair: I-potential traitator ye-resveratrol: i-vivo
ubungqina. Nat Rev Drug Discov 2006, 5:493�506.
151. Klink JC, Tewari AK, EMasko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst
I-MW, i-Pizzo SV, i-Freedland SJ: I-Resveratrol yenza kube nzima ukusinda kwiimpuku ze-SCID ezinomhlaza we-prostate xenografts ngendlela ethile ye-cell-line, ngemiphumo ephazamisayo kwiindlela ze-oncogenic. Prostate 2013, 73:754�762.
152. Huang EC, Zhao Y, Chen G, Baek SJ, McEntee MF, Minkin S, Biggerstaff JP,
UWhelan J: UZyflamend, umxube we-polyherbal, phantsi ulawula isigaba I kunye
iklasi II histone deacetylases kwaye yandisa amazinga e-P21 kwi-castrate-resistant
iiseli zomhlaza zomzimba. I-BMC Incedisa i-Altern Med 2014, i-14: i-68.
153. Huang EC, McEntee MF, Whelan J: Zyflamend, inhlanganisela yemifuno
izicatshulwa, iyanciphisa ukukhula kwe-tumor kwimizekelo ye-murine xenograft
umhlaza wedlala lesinyi. Nutr Cancer 2012, 64:749�760.
154. Yan J, Xie B, uCapodice JL, Katz AE: I-Zyflamend inqanda ibinzana kwaye
umsebenzi we-androgen receptor kwaye isebenzisane ngokuvumelana ne-bicalutimide
ukuthintela ukukhula kweeseli zomhlaza wedlala lobudoda. Prostate 2012, 72:244-252.
155. Kunnumakkara AB, Sung B, uRavindran J, Diagaradjane P, Deorukhkar A, Dey
S, Koca C, Tong Z, Gelovani JG, Guha S, Krishnan S, BB Aggarwal: Zyflamend
ukukhupha ukukhula kunye nokukhuthaza izicubu ze-pancreatic
i-gemcitabine kwimodeli ye mouse ye-orthotopic ngokumodulations
iithagethi ezininzi. Int J Cancer 2012, 131:E292�E303.
156. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson
MC, Stone BA, Katz AE: Zyflamend kumadoda ane-prostatic-grade grade
i-intraepithelial neoplasia: iziphumo zesigaba sesi-1 sesilingo seklinikhi. J Soc Integration
ONcol 2009, 7:43�51.
157. Rafailov S, Cammack S, Stone BA, Katz AE: Indima yeZyflamend,
i-antibal-inflammatory, njenge-artificial artificial agent against
umhlaza wedlala lobudoda: ingxelo yetyala. Integr Cancer Ther 2007, 6:74�76.
158. U-Askari F, uParizi MK, uJessri M, uRashidkhani B: Iziqhamo kunye nemifuno
Ubudlelwane nomhlaza wesibeleko kumadoda aseIran: isifundo solawulo lwetyala.
Asian Pac J Cancer Prev 2014, 15:5223�5227.
159. Liu B, Mao Q, Cao M, Xie L: Imifuno yeCruciferous ingeniso kunye nobungozi
umhlaza wedlala lobudoda: uhlalutyo lwemeta. Int J Urol 2012, 19:134�141.
160. Richman EL, uCarroll PR, uKhan JM: Imifuno kunye neziqhamo zithatha emva
ukuxilongwa kunye nomngcipheko wokuqhubela umdlavuza wesibeletho. I-J J Cancer 2012,
131: 201-210.
161. Hsing AW, Chokkalingam AP, Gao YT, MP MP, uDeng J, Gridley G,
I-Fraumeni JF Jr: Imifuno ye-allium kunye nomngcipheko womhlaza wesibeletho: a
uphononongo olusekwe ebantwini. J Natl Cancer Inst 2002, 94:1648�1651.
162. Chan R, Lok K, Woo J: Umhlaza wesifo seprostate kunye nokusetyenziswa kwemifuno.
I-Mol Nutr Food Res 2009, 53:201�216.
163. Thomas R, Williams M, Sharma H, Chaudry A, uBellamy P: Umntu oyimpumputhe,
I-trialbo elawulwa yi-placebo yokuhlola i-impact ye-a
I-polyphenol-rich rich supplement kwi-PSA ukuqhubela phambili kumadoda
kunye nomhlaza wesibeletho-i-UK NCRN Pomi-T. Prostate Cancer Prostatic
Dis 2014, 17:180-186.
164. I-Yang CM, i-Lu IH, i-Chen HY, i-Hu ML: I-Lycopene inqanda ukusabalala kwayo
kunye ne-androgen-kuxhomekeke kwiiyununu zesalathisi zesalathisi zomntu ngokusebenzisa
Indlela ye-PPARgamma-LXRalpha-ABCA1. J Nutr Biochem 2012, 23:8�17.
165. Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, van Breemen RB: Imiphumo
i-lycopene kwiprotein yeprotein kwi-primary prostatic epithelial yabantu
iiseli. Cancer Prev Res (Phila) 2013, 6:419�427.
166. UBoileau TW, uLiao Z, uKim S, uLimeshow S, uErdman JW Jr, uClinton SK: Iprostate
i-carcinogenesis kwi-N-methyl-N-nitrosourea (i-NMU)
Iinqongi zondla i-tomato powder, i-lycopene, okanye ukutya okunomlinganiselo wokutya. J Natl
ICancer Inst 2003, 95:1578�1586.
167. I-Konijeti R, uHenning S, uM Moro, uSheikh A, uElashoff D, uShapiro A, Ku M,
Uthi JW, uHeber D, Cohen P, Aronson WJ: Chemoprevention of prostate
umhlaza nge-lycopene kwimodeli ye-TRAMP. Prostate 2010, 70:1547&1554.
168. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, uWillett WC: Lowo
ukufundwa kweemveliso zetamatato, i-lycopene, kunye nomngcipheko womhlaza wesibeletho. J Natl
ICancer Inst 2002, 94:391�398.
169. Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E:
I-lycopene yokutya, i-angiogenesis, kunye nomhlaza wesifo seprotate: umntu ozayo
ukufundisisa kwixesha elithile le-antigen. I-Natl Cancer Inst 2014,
106: djt430.
170. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer
UMJ: Umngcipheko wesifo somhlaza wesifo se-prostate kumadoda aneeplasma ephakamileyo
amanqanaba: iziphumo zohlalutyo olulindelekileyo. Umhlaza Res 1999, 59:1225�1230.
171. I-Kristal AR, Kuze kube yiC, i-Platz EA, ingoma X, i-King IB, i-Neuhouser ML, i-Ambrosone CB, i-
I-Thompson IM: Inkxalabo ye-Serum yecycopene kunye nomngcipheko womhlaza wesifo somhlaza:
iziphumo ezivela kwi-Prostate Cancer Prevention Trial. Cancer Epidemiol
Biomarkers Prev 2011, 20:638�646.
172. I-Kirsh VA, iMayne ST, uPeter U, i-Chatterjee N, i-Leitzmann MF, iDixon LB, i-Urban
DA, Crawford ED, Hayes RB: Ufuna ukufundisisa i-lycopene kunye ne-tomato
ukuveliswa kwemveliso kunye nomngcipheko womhlaza wesibeletho. Cancer Epidemiol Biomarkers
Edlulileyo 2006, 15:92�98.
173. Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C, Hong
GM, Borro M, Simmaco M: Uxinzelelo lwe-prostate oluphantsi lwe-lycopene
inxulumene nophuhliso lomhlaza wesibeletho kwizigulane eziphezulu
I-prostatic intraepithelial neoplasia. Int J Mol Sci 2014, 15:1433�1440.
174. UKucuk O, uSarkar FH, uDjuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M,
I-Bertram JS, i-Wood DP Jr: Iimpembelelo zokuncedisa i-lycopene kwizigulane
nomhlaza wedlala lesinyi. Exp Biol Med (Maywood) 2002, 227:881�885.
175. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van
Breemen R, Ashton D, Bowen PE: Umonakalo we-DNA we-DNA kwiprotate
izigulane zomhlaza ezidla i-tomes-sauce-bases-food-based
ungenelelo. J Natl Cancer Inst 2001, 93:1872�1879.
176. I-Breemen RB, i-Sharifi R, i-Viana M, i-Pajkovic N, i-Zhu D, i- Yuan L, i-Yang Y, i-
Bowen PE, Stacewicz-Sapuntzakis M: Iimpembelelo ze-antioxidant ze-lycopene
Amadoda aseMerika aseMelika anomhlaza wesibeletho okanye i-benign prostate hyperplasia:
ulingo olungenamkhethe, olulawulwayo. Cancer Prev Res (Phila) 2011, 4:711�718.
177. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, iMorrison DS: Ikhofi
ukusetyenziswa kunye nomngcipheko womhlaza wesifo somhlaza: ubungqina obuninzi bokungena
ulwalamano. I-J 2012, i-11: i-42.
178. UWilson KM, uKasperzyk JL, uRider JR, uKenfield S, iVan Dam RM, uStampfer MJ,
UGiovannucci E, uMucci LA: Ukusetyenziswa kwekhofi kunye nomngcipheko womhlaza wesifo somhlaza
kunye nokuqhubela phambili kwi-Health Professionals Follow-up Study. J Natl
ICancer Inst 2011, 103:876�884.
179. Bosire C, uSampampfer MJ, uAstern AF, iWilson KM, iPark Y, iSinha R: Ikofi
ukusetyenziswa kunye nomngcipheko womhlaza womhlaza wesifo somhlaza wesifo se-prostate
I-NIH-AARP Ukutya kunye neSifundo seMpilo. Ulawulo lwe-Cancer Causes Control 2013, 24:1527�1534.
180. Arab L, Su LJ, Steck SE, Ang A, Fontham ET, Bensen JT, Mohler JL: Ikofi
ukusetyenziswa kunye nomdlavuza wesibeletho phakathi kweAfrika kunye
Abantu baseMerika baseCaucasus kwisifundo esisekelwe kubantu. I-Cancer Cancer 2012,
64: 637-642.
181. I-Phillips RL, iDawndon DA: Umbutho wenyama kunye nekhofi esebenzisa i-cancer
kwilungu elikhulu, isifuba kunye neprotate phakathi kweeSabatha zamaSabatha:
iziphumo zokuqala. Umhlaza Res 1983, 43:2403 s�2408s.
182. Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S,
I-Chien HT, i-Blot ye-BJ: Ukutya, ukusetyenziswa kwecuba, kunye nomhlaza womhlaza wesifo seprotate: iziphumo
kwiSifundo soBuzalwana bamaLutheran. Cancer Res 1990,
50: 6836-6840.
183. Cao S, Liu L, Yin X, Wang Y, Liu J, Lu Z: Ukusetyenziswa kwekhofi kunye nobungozi
Umhlaza wesifo seprotate: uhlalutyo lwe-meta-uphando lwabantu abaza kuhlola.
I-Carcinogenesis 2014, 35: 256�261.
184. Nordmann AJ, Suter-Zimmermann K, Bucher HC, uShai I, uTuttle KR,
U-Estruch R, uBriel M: Uhlalutyo lwe-Meta ukuthelekisa iMedithera ukuya kwi-fat-fat
izidlo zokuguqulwa kwezinto ezinobungozi bomzimba. Am J Med 2011,
124:841; 851. e842.
185. I-Kapiszewska M: Imifuno yokutya yokutya njengento efanelekileyo
into ebangela umdlavuza wokukhusela ukukhusela. IMedithera
amanye amazwe aseYurophu. IForam Nutr 2006, 59:130�153.
186. UKenfield SA, uDupre N, Richman EL, Stampfer MJ, Chan JM, Giovannucci EL:
Ukutya kweMedithera kunye nomngcipheko womhlaza wesifo seprotate kunye nokufa kwabantu kwiMpilo
Uphononongo lokulandelela iiNgcali. I-Eur Urol 2014, 65:887�894.
187. Ambrosini GL, Fritschi L, de Klerk NH, iMackerras D, Leavy J: Iipatheni zokutya
zichongiwe ukuhlalutya kwezinto kunye nomngcipheko womhlaza wesifo seprotate: ukulawulwa kwimeko
ukufunda eNtshona Ostreliya. Ann Epidemiol 2008, 18:364�370.
188. I-PD ye-Baade, i-Youlden DR, i-Krnjacki LJ: I-epidemiology yamazwe ngamazwe e-prostate
umhlaza: ukusabalaliswa kweendawo kunye nemigangatho yelizwe. I-Mol Nutrition Food Res
2009, 53:171�184.
189. Muller DC, Severi G, Baglietto L, Krishnan K, DR isiNgesi, i-Hopper JL, iGiles GG:
Iipateni zokutya kunye nomngcipheko womhlaza wesifo somhlaza. I-Cancer Epidemiol Biomarkers Ngaphambili
2009, 18:3126�3129.
190. I-Tseng M, iBreslow RA, iDevVisis RF, iZiegler RG: Iipatheni zesidlo kunye neprotate
Ingozi yomhlaza kwiNational Health and Nutrition Examination Survey
Iqela loFundo lokuPhumela kwe-epidemiological. I-Cancer Epidemiol Biomarkers Ngaphambili
2004, 13:71�77.
191. UWu K, uHu FB, uWillett WC, uGiovannucci E: Iindlela zokutya kunye nomngcipheko
Umdlavuza wesibeletho e-US amadoda. I-Cancer Epidemiol Biomarkers I-2006,
15: 167-171.
192. Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C,
UGao B, uCarroll P, u-Ornish D: Indlela yokuphila kunye nomgangatho ofanelekileyo wezempilo
Abantu abanomdlavuza wesibeletho balawulwa ngokuqwalasela. Urology
2006, 67:125�130.
193. Iiparsons JK, uNewman VA, Mohler JL, Pierce JP, Flatt S, Marshall J: Izidlo
Ukuguqulwa kwezigulane ezineengxaki zomhlaza wesifo somhlaza kwisifo sokuqapha: a
uphononongo olunokwenzeka olungenamkhethe, lwamaziko amaninzi. BJU Int 2008, 101:1227�1231.
194. UMosher CE, uStorane R, iMorey MC, uSnyder DC, Cohen HJ, Miller PE,
U-Demark-Wahnefried W: Iinkampani phakathi kwezinto zokuphila kunye nomgangatho
zobomi phakathi kwexesha elide lexesha elide, i-prostate, kunye nomhlaza omnyama
abasindileyo. Umhlaza 2009, 115:4001�4009.
195. Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A,
Trachtenberg J, uZlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH,
I-Fleshner NE: Ukuxuba umbutho phakathi kwesifo se-metabolic syndrome
kunye nomngcipheko womhlaza wesifo seprotate: uhlalutyo lweqela elikhulu lekliniki. Eur Urol 2014.
doi: 10.1016 / j.eururo.2014.01.040. [Epub ngaphambi kwexesha]
196. I-Esposito K, i-Chiodini P, iCapuano A, iBellastella G, iMextino MI, iParretta E,
I-Lenzi A, iGiugliano D: Impembelelo yesifo se-metabolic and components
ingozi yomhlaza wesifo seprotate: i-meta-analysis. J Endocrinol Invest Investment 2013,
36: 132-139.
197. Isebe lezoLimo laseMelika kunye neSebe lezeMpilo lase-US kunye
IiNkonzo zoLuntu. Izikhokelo zeZidlo zamaMerika, i-2010. I-7th edition.
IWashington, DC: I-Ofisi kaRhulumente yokuprinta i-US, uDisemba, i-2010.
